Development and Optimization of Zirconium-89 Production and Clinical TF-PET/CT Imaging Protocols for Breast Tumor Imaging and Immunotherapy Planning: A Review
Zirconium-89 (89Zr) has recently drawn significant interest to be a promising metallo-radionuclide for use in immuno-PET due to favorable decay characteristics. Despite all efforts that have been done over the last few years in the development of procedures for large-scale
production and purification of 89Zr and its stable coupling to mAbs as well as successful preclinical and clinical 89Zr immuno-positron emission tomography (PET) studies, there is still gap for exploring new peptide-based pharmaceuticals radiolabeled with 89Zr
and the development of 89Zr immuno-PET imaging protocols. The objectives of this study is intended to review the recent development and optimization of 89Zr production and to discuss the 89Zr immuno-PET clinical imaging applications for breast cancer. In addition,
the 89Zr PET imaging safety and protocols as well as the potential use of 89Zr in 3-gamma PET Imaging are reviewed.
Keywords: BREAST CANCER; MOLECULAR IMAGING; MONOCLONAL ANTIBODIES; MONOCLONAL ANTIBODY (MAB); PET/CT; ZIRCONIUM-89
Document Type: Review Article
Publication date: 01 February 2019
- Journal of Medical Imaging and Health Informatics (JMIHI) is a medium to disseminate novel experimental and theoretical research results in the field of biomedicine, biology, clinical, rehabilitation engineering, medical image processing, bio-computing, D2H2, and other health related areas.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content